<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563823</url>
  </required_header>
  <id_info>
    <org_study_id>CRCA-CCTC-CAMEL02</org_study_id>
    <secondary_id>CDR0000576458</secondary_id>
    <secondary_id>EU-20787</secondary_id>
    <secondary_id>EUDRACT-2005-004710-33</secondary_id>
    <secondary_id>CCLG-Camel-02</secondary_id>
    <secondary_id>ISRCTN00191981</secondary_id>
    <nct_id>NCT00563823</nct_id>
  </id_info>
  <brief_title>Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery</brief_title>
  <official_title>A Phase II Study to Evaluate the Efficacy and Safety of PTK787 in Patients With Metastatic Cutaneous Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vatalanib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well vatalanib works in treating patients with&#xD;
      metastatic cutaneous melanoma that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the response rate in patients with unresectable metastatic cutaneous&#xD;
           melanoma treated with vatalanib.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the time to progression in these patients.&#xD;
&#xD;
        -  To determine the 6-month and 1-year survival of these patients.&#xD;
&#xD;
        -  To determine the overall survival of these patients.&#xD;
&#xD;
        -  To determine the safety and toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral vatalanib twice daily on days 1-28. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 8 weeks and then periodically&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate as assessed by RECIST every 8 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 6 months and 1 year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by NCI CTCAE v3.0 at 2 weeks and then every 4 weeks</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vatalanib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic cutaneous melanoma&#xD;
&#xD;
               -  Unresectable disease&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 bidimensionally measurable lesion by clinical or&#xD;
             radiological techniques (i.e., chest x-ray, CT scan, or conventional MRI scan) using&#xD;
             RECIST criteria&#xD;
&#xD;
          -  No history or presence of CNS disease (i.e., primary brain tumor, malignant seizures,&#xD;
             clinically symptomatic CNS metastases, or carcinomatous meningitis)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 x ULN (≤ 5 if liver metastases are present)&#xD;
&#xD;
          -  Transaminases ≤ 3 x ULN (≤ 5 if liver metastases are present)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Total urinary protein ≤ 500 mg by 24-hour urine collection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  No history of other malignant disease except adequately treated nonmelanoma skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other serious or uncontrolled illness which, in the opinion of the investigator,&#xD;
             precludes study entry&#xD;
&#xD;
          -  No medical or psychiatric condition that precludes giving informed consent&#xD;
&#xD;
          -  No history of renal disease (e.g., glomerulonephritis) or renal vascular disease&#xD;
&#xD;
          -  No acute or chronic active liver disease (e.g., hepatitis or cirrhosis)&#xD;
&#xD;
          -  No concurrent severe and/or uncontrolled medical conditions that would compromise&#xD;
             participation in the study, including any of the following:&#xD;
&#xD;
               -  Uncontrolled high blood pressure, history of labile hypertension, or history of&#xD;
                  poor compliance with an antihypertensive regimen&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Serious uncontrolled cardiac arrhythmia&#xD;
&#xD;
               -  Uncontrolled diabetes&#xD;
&#xD;
               -  Active or uncontrolled infection&#xD;
&#xD;
          -  No impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of vatalanib including, but not limited to, any of the following&#xD;
             conditions:&#xD;
&#xD;
               -  Ulcerative disease&#xD;
&#xD;
               -  Uncontrolled nausea&#xD;
&#xD;
               -  Vomiting&#xD;
&#xD;
               -  Diarrhea which might result in malabsorption&#xD;
&#xD;
               -  Any known malabsorption syndrome&#xD;
&#xD;
               -  Bowel obstruction&#xD;
&#xD;
               -  Inability to swallow the capsules/tablets&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  Prior adjuvant therapy allowed&#xD;
&#xD;
          -  Prior radiotherapy allowed&#xD;
&#xD;
               -  Measurable target lesions must not have been irradiated&#xD;
&#xD;
          -  No more than one line of prior systemic therapy for advanced melanoma&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy, immunotherapy, or investigational agent&#xD;
&#xD;
          -  More than 2 weeks since prior surgery&#xD;
&#xD;
          -  No concurrent warfarin or other similar oral anticoagulants that are metabolized by&#xD;
             the cytochrome p450 system&#xD;
&#xD;
               -  Concurrent heparin allowed&#xD;
&#xD;
          -  Concurrent radiotherapy for symptomatic disease is allowed, provided the lesions being&#xD;
             irradiated contribute ≤ 20% of the sum of the longest diameter for all target lesions&#xD;
             being used to determine response&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pippa Corrie, PhD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Cook N, Basu B, Biswas S, Kareclas P, Mann C, Palmer C, Thomas A, Nicholson S, Morgan B, Lomas D, Sirohi B, Mander AP, Middleton M, Corrie PG. A phase 2 study of vatalanib in metastatic melanoma patients. Eur J Cancer. 2010 Oct;46(15):2671-3. doi: 10.1016/j.ejca.2010.07.014. Epub 2010 Aug 25.</citation>
    <PMID>20800475</PMID>
  </results_reference>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>November 22, 2007</study_first_submitted>
  <study_first_submitted_qc>November 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vatalanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

